Cargando…

Positron Emission Tomography (PET) Radiopharmaceuticals in Multiple Myeloma

Multiple myeloma (MM) is a plasma cell disorder, characterized by clonal proliferation of malignant plasma cells in the bone marrow. Bone disease is the most frequent feature and an end-organ defining indicator of MM. In this context, imaging plays a pivotal role in the management of the malignancy....

Descripción completa

Detalles Bibliográficos
Autores principales:	Sachpekidis, Christos, Goldschmidt, Hartmut, Dimitrakopoulou-Strauss, Antonia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6982887/ https://www.ncbi.nlm.nih.gov/pubmed/31905752 http://dx.doi.org/10.3390/molecules25010134

Ejemplares similares

Positron Emission Tomography in Merkel Cell Carcinoma
por: Sachpekidis, Christos, et al.
Publicado: (2020)

Functional Imaging with (18)F-FDG PET/CT and Diffusion Weighted Imaging (DWI) in Early Response Evaluation of Combination Therapy of Elotuzumab, Lenalidomide, and Dexamethasone in a Relapsed Multiple Myeloma Patient
por: Sachpekidis, Christos, et al.
Publicado: (2017)

Can (18)F-NaF PET/CT before Autologous Stem Cell Transplantation Predict Survival in Multiple Myeloma?
por: Sachpekidis, Christos, et al.
Publicado: (2020)

The prognostic significance of [(18)F]FDG PET/CT in multiple myeloma according to novel interpretation criteria (IMPeTUs)
por: Sachpekidis, Christos, et al.
Publicado: (2021)

Quantitative, Dynamic (18)F-FDG PET/CT in Monitoring of Smoldering Myeloma: A Case Report
por: Sachpekidis, Christos, et al.
Publicado: (2021)

Positron Emission Tomography as a Surrogate Marker for Evaluation of Treatment Response in Patients with Desmoid Tumors under Therapy with Imatinib
por: Kasper, Bernd, et al.
Publicado: (2013)

Positron Emission Tomography Radiopharmaceuticals in Differentiated Thyroid Cancer
por: Sakulpisuti, Chaninart, et al.
Publicado: (2022)

Imaging Features of Multiple Myeloma Extramedullary Lesions in the Liver with 18F-FDG PET/CT, Contrast-Enhanced CT and MRI
por: Papamichail, Dimitris, et al.
Publicado: (2019)

Current Radiopharmaceuticals for Positron Emission Tomography of Brain Tumors
por: Jung, Ji-hoon, et al.
Publicado: (2018)

Long axial field of view (LAFOV) PET-CT: implementation in static and dynamic oncological studies
por: Dimitrakopoulou-Strauss, Antonia, et al.
Publicado: (2023)

Application of an artificial intelligence-based tool in [(18)F]FDG PET/CT for the assessment of bone marrow involvement in multiple myeloma
por: Sachpekidis, Christos, et al.
Publicado: (2023)

Kinetic modeling and parametric imaging with dynamic PET for oncological applications: general considerations, current clinical applications, and future perspectives
por: Dimitrakopoulou-Strauss, Antonia, et al.
Publicado: (2020)

Assessment of glucose metabolism and cellular proliferation in multiple myeloma: a first report on combined (18)F-FDG and (18)F-FLT PET/CT imaging
por: Sachpekidis, C., et al.
Publicado: (2018)

Chelators for copper radionuclides in positron emission tomography radiopharmaceuticals()
por: Cai, Zhengxin, et al.
Publicado: (2013)

Positron Emission Tomography (PET) Imaging of Multiple Myeloma in a Post-Treatment Setting
por: Ferrarazzo, Giulia, et al.
Publicado: (2021)

PET Diagnostic Molecules Utilizing Multimeric Cyclic RGD Peptide Analogs for Imaging Integrin α(v)β(3) Receptors
por: Liolios, Christos, et al.
Publicado: (2021)

Quality control of positron emission tomography radiopharmaceuticals: An institutional experience
por: Shukla, Jaya, et al.
Publicado: (2013)

Positron emission tomography: Evolving modalities, radiopharmaceuticals and professional collaboration
por: Ayesa, Sally L., et al.
Publicado: (2022)

Comparison of functional imaging in multiple myeloma patients: Indication for hybrid-imaging with PET/MRI?
por: Mosebach, J, et al.
Publicado: (2015)

Tau Biomarkers in Dementia: Positron Emission Tomography Radiopharmaceuticals in Tauopathy Assessment and Future Perspective
por: Ricci, Maria, et al.
Publicado: (2021)

Dual‐Nuclide Radiopharmaceuticals for Positron Emission Tomography Based Dosimetry in Radiotherapy
por: Wurzer, Alexander, et al.
Publicado: (2017)

Radiogenomic Analysis of F-18-Fluorodeoxyglucose Positron Emission Tomography and Gene Expression Data Elucidates the Epidemiological Complexity of Colorectal Cancer Landscape
por: Vlachavas, Efstathios–Iason, et al.
Publicado: (2019)

Positron Emission Tomography (PET) in Oncology
por: Gallamini, Andrea, et al.
Publicado: (2014)

Assessment of early metabolic progression in melanoma patients under immunotherapy: an (18)F-FDG PET/CT study
por: Sachpekidis, Christos, et al.
Publicado: (2021)

The Use of Positron Emission Tomography in Soft Tissue Sarcoma Patients under Therapy with Trabectedin
por: Kasper, Bernd, et al.
Publicado: (2009)

Imaging therapy response of gastrointestinal stromal tumors (GIST) with FDG PET, CT and MRI: a systematic review
por: Dimitrakopoulou-Strauss, Antonia, et al.
Publicado: (2017)

Modern radiopharmaceuticals for lung cancer imaging with positron emission tomography/computed tomography scan: A systematic review
por: Theodoropoulos, Athanasios S, et al.
Publicado: (2020)

Assessment of radiopharmaceutical retention for vascular access ports using positron emission tomography imaging
por: Gossman, Michael S., et al.
Publicado: (2017)

Quantitative Dynamic (18)F-FDG PET/CT in Survival Prediction of Metastatic Melanoma under PD-1 Inhibitors
por: Sachpekidis, Christos, et al.
Publicado: (2021)

Embryo/Fetus Doses from (18)F-Fludeoxyglucose Radiopharmaceutical in Positron Emission Tomography/ Computed Tomography
por: Işıkçı, Nazenin İpek, et al.
Publicado: (2022)

Myelin positron emission tomography (PET) imaging in multiple sclerosis
por: de Paula Faria, Daniele
Publicado: (2020)

The prognostic value of [(18)F]FDG PET/CT based response monitoring in metastatic melanoma patients undergoing immunotherapy: comparison of different metabolic criteria
por: Sachpekidis, Christos, et al.
Publicado: (2023)

Application of the long axial field-of-view PET/CT with low-dose [(18)F]FDG in melanoma
por: Sachpekidis, Christos, et al.
Publicado: (2022)

Fractal and multifractal analysis of PET/CT images of metastatic melanoma before and after treatment with ipilimumab
por: Breki, Christina-Marina, et al.
Publicado: (2016)

Automated synthesis of radiopharmaceuticals for positron emission tomography: an apparatus for labelling with [(11)C] methyl iodide (MIASA)
por: Cork, D. G., et al.
Publicado: (1994)

Automated synthesis of radiopharmaceuticals for positron emission tomography: an apparatus for [1-(11)C] labeled carboxylic acid
por: Yajima, Kazuyoshi, et al.
Publicado: (1995)

Quantitative approaches of dynamic FDG-PET and PET/CT studies (dPET/CT) for the evaluation of oncological patients
por: Dimitrakopoulou-Strauss, Antonia, et al.
Publicado: (2012)

Interim [(18)F]FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma
por: Sachpekidis, Christos, et al.
Publicado: (2020)

Can physiologic colonic [(18)F]FDG uptake in PET/CT imaging predict response to immunotherapy in metastatic melanoma?
por: Sachpekidis, Christos, et al.
Publicado: (2023)

The Role of Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography in Evaluating the Response to Treatment in Patients with Multiple Myeloma
por: Caldarella, Carmelo, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_pcau81sj349165asqsbqp65l9r